CLINICAL_TRIALS
trial_result
· 2014-12-23
Clinical Trial Update: A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) [Phase 1]
Summary
This clinical trial update reports that GNKG168 in relapsed or refractory B-cell chronic lymphocytic leukemia (Phase I) has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: SBI Biotech Co., Ltd. | Conditions: Leukemia | Phase 1 | Status: TERMINATED